{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:09Z","timestamp":1791382209292,"version":"4.3.3"},"reference-count":134,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurofibromatosis (NF) is a neurocutaneous syndrome characterized by the development of tumors of the central or peripheral nervous system including the brain, spinal cord, organs, skin, and bones. There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in &lt;1%. The NF1 gene is located on chromosome 17q11.2, which encodes for a tumor suppressor protein, neurofibromin, that functions as a negative regulator of Ras\/MAPK and PI3K\/mTOR signaling pathways. The NF2 gene is identified on chromosome 22q12, which encodes for merlin, a tumor suppressor protein related to ezrin-radixin-moesin that modulates the activity of PI3K\/AKT, Raf\/MEK\/ERK, and mTOR signaling pathways. In contrast, molecular insights on the different forms of SWN remain unclear. Inactivating mutations in the tumor suppressor genes SMARCB1 and LZTR1 are considered responsible for a majority of cases. Recently, treatment strategies to target specific genetic or molecular events involved in their tumorigenesis are developed. This study discusses molecular pathways and related targeted therapies for NF1, NF2, and SWN and reviews recent clinical trials which involve NF patients.<\/jats:p>","DOI":"10.3390\/ijms22115850","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:22:15Z","timestamp":1622420535000},"page":"5850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":241,"title":["Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-901X","authenticated-orcid":false,"given":"Ryota","family":"Tamura","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Kawasaki Municipal Hospital, Shinkawadori, Kanagawa, Kawasaki-ku 210-0013, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: A genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00401-019-02002-2","article-title":"An update on the central nervous system manifestations of neurofibromatosis type 1","volume":"139","author":"Nix","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-0036-1579766","article-title":"Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis","volume":"5","author":"Kresak","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.2016.71.7199","article-title":"CNS Tumors in Neurofibromatosis","volume":"35","author":"Campian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of neurofibromatosis type 1 in the Finnish population","volume":"20","author":"Uusitalo","year":"2018","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","article-title":"The clinical and diagnostic implications of mosaicism in the neurofibromatoses","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Legius, E., Messiaen, L., Wolkenstein, P., Pancza, P., Avery, R.A., Berman, Y., Blakeley, J., Babovic-Vuksanovic, D., Cunha, K.S., and Ferner, R. (2021). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation. Genet. Med., 19.","DOI":"10.1038\/s41436-021-01170-5"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00197259","article-title":"Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes","volume":"88","author":"Stephens","year":"1992","journal-title":"Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/320121","article-title":"Mortality in neurofibromatosis 1: An analysis using U.S. death certificates","volume":"68","author":"Rasmussen","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw. Open."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2008.065243","article-title":"SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype","volume":"46","author":"Pasmant","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1093\/emboj\/17.15.4313","article-title":"Structural analysis of the GAP-related domain from neurofibromin and its implications","volume":"17","author":"Scheffzek","year":"1998","journal-title":"EMBO J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/exd.13212","article-title":"Neurofibromatosis type 1 (NF1) gene: Beyond caf\u00e9 au lait spots and dermal neurofibromas","volume":"26","author":"Peltonen","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2006.00639.x","article-title":"Neurofibromin: A general outlook","volume":"70","author":"Tajara","year":"2006","journal-title":"Clin. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000126545","article-title":"NF1 mutational spectrum","volume":"16","author":"Messiaen","year":"2008","journal-title":"Monogr. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/humu.9193","article-title":"Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors","volume":"22","author":"Kluwe","year":"2003","journal-title":"Hum. Mutat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant peripheral nerve sheath tumors","volume":"19","author":"Farid","year":"2014","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/humu.9429","article-title":"The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs)","volume":"27","author":"Upadhyaya","year":"2006","journal-title":"Hum. Mutat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41436-018-0269-0","article-title":"Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): An update of genotype-phenotype correlation","volume":"21","author":"Koczkowska","year":"2019","journal-title":"Genet. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","article-title":"Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848","volume":"102","author":"Koczkowska","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.23929","article-title":"Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: Genotype-phenotype study in neurofibromatosis type 1","volume":"41","author":"Koczkowska","year":"2020","journal-title":"Hum. Mutat."},{"key":"ref_25","first-page":"878","article-title":"Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia","volume":"8","author":"Quesnel","year":"1994","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","article-title":"Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects","volume":"15","author":"Messiaen","year":"2000","journal-title":"Hum. Mutat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1136\/jmg.40.10.e109","article-title":"Evaluation of genotype-phenotype correlations in neurofibromatosis type 1","volume":"40","author":"Castle","year":"2003","journal-title":"J. Med. Genet."},{"key":"ref_28","first-page":"105","article-title":"Bullous lung disease and neurofibromatosis type-1","volume":"77","author":"Nardecchia","year":"2012","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1017\/S1462399409001227","article-title":"Malignant peripheral nerve sheath tumour (MPNST): The clinical implications of cellular signalling pathways","volume":"11","author":"Katz","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"1","article-title":"Selumetinib: The first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma","volume":"8","author":"Mukhopadhyay","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1542\/peds.105.3.608","article-title":"Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children","volume":"105","author":"DeBella","year":"2000","journal-title":"Pediatrics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.eye.6702379","article-title":"Optic glioma warranting treatment in children","volume":"20","author":"Kaufman","year":"2006","journal-title":"Eye"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1101\/gad.8.9.1019","article-title":"Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues","volume":"8","author":"Brannan","year":"1994","journal-title":"Genes Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng0794-353","article-title":"Tumor predisposition in mice heterozygous for a targeted mutation in NF1","volume":"7","author":"Jacks","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1242\/dev.125.22.4359","article-title":"Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart","volume":"125","author":"Lakkis","year":"1998","journal-title":"Development"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/dbio.1999.9327","article-title":"Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects","volume":"212","author":"Lakkis","year":"1999","journal-title":"Dev. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q","article-title":"Neurofibromatosis 1 (NF1) heterozygosity results in a cell\u2014Autonomous growth advantage for astrocytes","volume":"33","author":"Bajenaru","year":"2001","journal-title":"Glia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1038\/sj.onc.1202829","article-title":"Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation","volume":"18","author":"Gutmann","year":"1999","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1101\/gad.862101","article-title":"Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain","volume":"15","author":"Zhu","year":"2001","journal-title":"Genes Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/86898","article-title":"Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1","volume":"27","author":"Costa","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1038\/ncomms8391","article-title":"Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling","volume":"6","author":"Zuckermann","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/0008-5472.CAN-07-6867","article-title":"Pten haploinsufficiency accelerates formation of high-grade astrocytomas","volume":"68","author":"Kwon","year":"2008","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/79075","article-title":"Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects","volume":"26","author":"Reilly","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.1863","article-title":"Development of a novel mouse glioma model using lentiviral vectors","volume":"15","author":"Marumoto","year":"2009","journal-title":"Nat. Med."},{"key":"ref_46","first-page":"8573","article-title":"Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity","volume":"63","author":"Bajenaru","year":"2003","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s42003-018-0163-y","article-title":"Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1","volume":"1","author":"Isakson","year":"2018","journal-title":"Commun Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e120402","DOI":"10.1172\/jci.insight.120402","article-title":"A porcine model of neurofibromatosis type 1 that mimics the human disease","volume":"3","author":"White","year":"2018","journal-title":"JCI Insight."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41436-019-0598-7","article-title":"Incidence of mosaicism in 1055 de novo NF2 cases: Much higher than previous estimates with high utility of next-generation sequencing","volume":"22","author":"Evans","year":"2020","journal-title":"Genet. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jmg.2006.047753","article-title":"Mosaicism in neurofibromatosis type 2: An update of risk based on uni\/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification","volume":"44","author":"Evans","year":"2007","journal-title":"J. Med. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol. Neurotol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1212\/WNL.0000000000007898","article-title":"Peripheral nervous system alterations in infant and adult neurofibromatosis type 2","volume":"93","author":"Godel","year":"2019","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/lary.25976","article-title":"Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration","volume":"126","author":"Picry","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): A clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awf115","article-title":"Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2","volume":"125","author":"Sperfeld","year":"2002","journal-title":"Brain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1212\/WNL.0000000000008065","article-title":"Neurofibromatosis 2 in children presenting during the first decade of life","volume":"93","author":"Gaudioso","year":"2019","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archopht.125.3.389","article-title":"Ocular pathologic findings of neurofibromatosis type 2","volume":"125","author":"McLaughlin","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/WNO.0000000000000675","article-title":"Neurofibromatosis Type 2-Related Eye Disease Correlated with Genetic Severity Type","volume":"39","author":"Painter","year":"2019","journal-title":"J. Neuroophthalmol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2017.5464","article-title":"Early Genetic Diagnosis of Neurofibromatosis Type 2 from Skin Plaque Plexiform Schwannomas in Childhood","volume":"154","author":"Castellanos","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jmg.40.2.109","article-title":"Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas","volume":"40","author":"Kluwe","year":"2003","journal-title":"J. Med. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/jmg.40.6.459","article-title":"Somatic mosaicism in neurofibromatosis 2: Prevalence and risk of disease transmission to offspring","volume":"40","author":"Moyhuddin","year":"2003","journal-title":"J. Med. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","article-title":"Further genotype\u2014Phenotype correlations in neurofibromatosis 2","volume":"77","author":"Selvanathan","year":"2010","journal-title":"Clin. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset","volume":"48","author":"Smith","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jmedgenet-2015-103290","article-title":"Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients","volume":"52","author":"Hexter","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1399-0004.2007.00778.x","article-title":"Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?","volume":"71","author":"Evans","year":"2007","journal-title":"Clin. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/lary.27554","article-title":"Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 gene","volume":"129","author":"Evans","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02688690500081206","article-title":"Management of the patient and family with neurofibromatosis 2: A consensus conference statement","volume":"19","author":"Evans","year":"2005","journal-title":"Br. J. Neurosurg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/nou317","article-title":"Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas","volume":"17","author":"Dewan","year":"2015","journal-title":"Neuro. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1227\/01.NEU.0000255340.26027.53","article-title":"Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates","volume":"60","author":"Mathieu","year":"2007","journal-title":"Neurosurgery"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-010-0181-1","article-title":"Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2","volume":"98","author":"Sharma","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11701-007-0036-8","article-title":"The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy","volume":"1","author":"McClelland","year":"2007","journal-title":"J. Robot. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","article-title":"Malignant transformation in vestibular schwannoma: Report of a single case, literature search, and debate","volume":"121","author":"Seferis","year":"2014","journal-title":"J. Neurosurg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1215\/15228517-2007-027","article-title":"Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: Case report and review of the literature","volume":"9","author":"Balasubramaniam","year":"2007","journal-title":"Neuro Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","article-title":"VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate","volume":"26","year":"2005","journal-title":"Otol. Neurotol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"N12","DOI":"10.1227\/01.NEU.0000345342.96663.0A","article-title":"The role of bevacizumab in hearing preservation and tumor volume control in patients with vestibular schwannomas","volume":"65","author":"Komotar","year":"2009","journal-title":"Neurosurgery"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1212\/WNL.0000000000000997","article-title":"Clinical response to bevacizumab in schwannomatosis","volume":"83","author":"Blakeley","year":"2014","journal-title":"Neurology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","article-title":"Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: Report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy","volume":"126","author":"Eminowicz","year":"2012","journal-title":"J. Laryngol. Otol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.3892\/ol.2016.4347","article-title":"Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol. Neurotol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2011.38.2614","article-title":"Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: From bench to bedside","volume":"30","author":"Subbiah","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/RLU.0000000000000329","article-title":"Avastin scintigraphy in surveillance of bevacizumab treatment in a patient with neurofibromatosis type 2: A case report","volume":"39","author":"Versleijen","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/nop\/npv065","article-title":"Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: A systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients with Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00280-016-3046-2","article-title":"Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2","volume":"77","author":"Ouerdani","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/s41467-020-16007-z","article-title":"A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2","volume":"11","author":"Tamura","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol. Neurotol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-019-03388-5","article-title":"Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas","volume":"146","author":"Tamura","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MAO.0000000000002994","article-title":"Cochlear Implant Outcomes in Neurofibromatosis Type 2: Implications for Management","volume":"42","author":"Deep","year":"2021","journal-title":"Otol. Neurotol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/MLG.0b013e31804b1ae7","article-title":"Cochlear implantation in the neurofibromatosis type 2 patient: Long-term follow-up","volume":"117","author":"Neff","year":"2007","journal-title":"Laryngoscope"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-019-03182-3","article-title":"First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: Results of a live-video randomized control trial","volume":"143","author":"Funes","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jmg.2004.023705","article-title":"Multiple meningiomas: Differential involvement of the NF2 gene in children and adults","volume":"42","author":"Evans","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3171\/jns.1995.83.4.0596","article-title":"Evidence of meningioma infiltration into cranial nerves: Clinical implications for cavernous sinus meningiomas","volume":"83","author":"Larson","year":"1995","journal-title":"J. Neurosurg."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijrobp.2008.03.073","article-title":"Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors","volume":"73","author":"Wentworth","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","article-title":"Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2","volume":"139","author":"Osorio","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Nunes, F.P., Merker, V.L., Jennings, D., Caruso, P.A., di Tomaso, E., Muzikansky, A., Barker, F.G., Stemmer-Rachamimov, A., and Plotkin, S.R. (2013). Bevacizumab treatment for meningiomas in NF2: A retrospective analysis of 15 patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059941"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2176\/nmc.oa.2019-0194","article-title":"Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients","volume":"60","author":"Fujii","year":"2020","journal-title":"Neurol. Med. Chir."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.11.10.1253","article-title":"The NF2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation","volume":"11","author":"McClatchey","year":"1997","journal-title":"Genes Dev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1101\/gad.13.8.978","article-title":"Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein","volume":"13","author":"Giovannini","year":"1999","journal-title":"Genes Dev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1101\/gad.226302","article-title":"Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse","volume":"16","author":"Kalamarides","year":"2002","journal-title":"Genes Dev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","article-title":"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1750-3639.2007.00105.x","article-title":"Natural history of meningioma development in mice reveals: A synergy of Nf2 and p16(Ink4a) mutations","volume":"18","author":"Kalamarides","year":"2008","journal-title":"Brain Pathol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-4939-3615-1_4","article-title":"Generation of noninvasive, quantifiable, orthotopic animal models for NF2-associated schwannoma and meningioma","volume":"1427","author":"Burns","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.46.4.1072","article-title":"Schwannomatosis: A clinical and pathologic study","volume":"46","author":"MacCollin","year":"1996","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Plotkin, S.R., Bredella, M.A., Cai, W., Kassarjian, A., Harris, G.J., Esparza, S., Merker, V.L., Munn, L.L., Muzikansky, A., and Askenazi, M. (2012). Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035711"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: A retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","article-title":"Diagnostic criteria for schwannomatosis","volume":"64","author":"MacCollin","year":"2005","journal-title":"Neurology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PAS.0b013e3182380802","article-title":"Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with \u201cneuroblastoma-like\u201d schwannomatosis and a novel germline SMARCB1 mutation","volume":"36","author":"Carter","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s100480050060","article-title":"Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis","volume":"2","author":"Jacoby","year":"1999","journal-title":"Neurogenetics"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-011-0300-y","article-title":"Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri","volume":"13","author":"Christiaans","year":"2012","journal-title":"Neurogenetics"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jmg.2007.056499","article-title":"Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis","volume":"45","author":"Hadfield","year":"2008","journal-title":"J. Med. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1399-0004.2008.01060.x","article-title":"Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis","volume":"74","author":"Boyd","year":"2008","journal-title":"Clin. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1038\/onc.2010.363","article-title":"Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas","volume":"29","author":"Hadfield","year":"2010","journal-title":"Oncogene"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1399-0004.2009.01249.x","article-title":"SMARCB1\/INI1 maternal germ line mosaicism in schwannomatosis","volume":"77","author":"Hulsebos","year":"2010","journal-title":"Clin. Genet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/humu.20679","article-title":"Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas","volume":"29","author":"Sestini","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Rousseau, G., Noguchi, T., Bourdon, V., Sobol, H., and Olschwang, S. (2011). SMARCB1\/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol., 11.","DOI":"10.1186\/1471-2377-11-9"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10048-012-0319-8","article-title":"Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis","volume":"13","author":"Smith","year":"2012","journal-title":"Neurogenetics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pbc.22831","article-title":"Spectrum of SMARCB1\/INI1 mutations in familial and sporadic rhabdoid tumors","volume":"56","author":"Eaton","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jmg.2008.060152","article-title":"Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1","volume":"46","author":"Swensen","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00381-017-3340-2","article-title":"A mosaic pattern of INI1\/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas","volume":"33","author":"Caltabiano","year":"2017","journal-title":"Childs Nerv. Syst."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ng.2855","article-title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas","volume":"46","author":"Piotrowski","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000001129","article-title":"Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis","volume":"84","author":"Smith","year":"2015","journal-title":"Neurology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ng.2734","article-title":"The integrated landscape of driver genomic alterations in glioblastoma","volume":"5","author":"Frattini","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Algar, E.M., Muscat, A., Dagar, V., Rickert, C., Chow, C.W., Biegel, J.A., Ekert, P.G., Saffery, R., Craig, J., and Johnstone, R.W. (2009). Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004482"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2011.09.019","article-title":"Global identification of modular cullin-RING ligase substrates","volume":"147","author":"Emanuele","year":"2011","journal-title":"Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:08:56Z","timestamp":1760162936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":134,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115850"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115850","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]}}}